Loxagen Inc.

Palo Alto, CA

UEI
JN1TN2LJU7S3
CAGE
8TT30
Primary NAICS
622310 Specialty (except Psychiatric and Substance Abuse) Hospitals
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
2380 Santa Ana St, Palo Alto, CA 94303, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this… U01NS132332 National Institute of Neurological Disorders and Stroke (NIH) $2,951,289
A novel targeted therapy for subarachnoid hemorrhage R43NS124491 National Institute of Neurological Disorders and Stroke (NIH) $512,772

Quick answers

Is Loxagen Inc. registered in SAM.gov?

Yes. Loxagen Inc.'s SAM.gov registration is active through December 2, 2026.

What is Loxagen Inc.'s most recent federal award?

Loxagen Inc.'s most recent federal grant award is Testing the lipoxygenase inhibitor BPN-27332 as acute phase stroke treatment in the span network - the goal of this… (U01NS132332), from National Institute of Neurological Disorders and Stroke (NIH), on May 1, 2023.

On GovTribe

See Loxagen Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login